Mateos M-V, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P et al..  2018.  Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.. N Engl J Med. 378(6):518-528.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS et al..  2018.  Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.. N Engl J Med. 378(8):731-739.

Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y et al..  2017.  Recurrent genetic defects on chromosome 5q in myeloid neoplasms.. Oncotarget. 8(4):6483-6495.

Demicco EG, Wagner MJ, Maki RG, Gupta V, Iofin I, Lazar AJ, Wang W-L.  2017.  Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model.. Mod Pathol. 30(10):1433-1442.

de Geus SWL, Eskander MF, Kasumova GG, Ng SChau, Kent TS, Mancias JD, Callery MP, Mahadevan A, Tseng JF.  2017.  Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.. Cancer. 123(21):4158-4167.

Azzopardi S, Pang S, Klimstra DS, Du Y-CNancy.  2016.  p53 and p16/p19 Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells.. Neoplasia. 18(10):610-617.

Thomas AA, Fisher JL, Rahme GJ, Hampton TH, Baron U, Olek S, Schwachula T, C Rhodes H, Gui J, Tafe LJ et al..  2015.  Regulatory T cells are not a strong predictor of survival for patients with glioblastoma.. Neuro Oncol. 17(6):801-9.

Steinman J, Ariyan C, Rafferty B, Brady MS.  2014.  Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion.. J Surg Oncol. 109(5):405-9.

Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Bin Chen Y-, Neuberg DS, Fathi AT.  2013.  Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.. Cancer. 119(14):2620-9.